• The Journal of Korean Medicine
• /
• v.15 no.2 s.28
• /
• pp.198-211
• /
• 1994

After giuing some anti-high blood pressure medicine of boiled-compressed fluid and 5-Kinds factors(Hydralazine, Verapamil, Clonidine, Furosemide and Hydrochlorothiazide with Kangsimsan to animals in single or together. I got the following conclusion in comparing blood-pressure and pulse of circulating system with urinating operation. 1. By joint-use of Kangsimsan and Hydralazine. it was found out that the effect of blood-pressure lowering continues longer in together-use than in single. And I coule see that the number of pulse increased. 2. By joint-use of Kangsimsan and Verapamil. the blood-pressure lowering operation was kept better in together-use than in single. the number of pulse was not affected any. 3. By joint-use of Kangsimsan and Clonidine the blood-pressure lowering operation was not found out any concrete result. 4. By joint-use of Kangsimsan and Furosemide. the Remarkble effect of Urinization was recognized to be much better in joint-use than in single. 5. By joint-use of Kangsimsan and Hydrochlorothiazide. the suppressing effect of urinization was recognized to be much better in joint-use than in single. Therefore in consideration of the above study and observation. when the joint-use of Kangsimsan and the blood-pressure lowering medicine. Hydralazine and Verapamil. the period of blood-pressure lowering was kept and I can conclude that in case of joint-use of Furosemide, a kind of good urinization. the effect of urinization by Furosemide is increased, but that of Hydrochlorothiazide is disturbed.

• The Korean Journal of Pharmacology
• /
• v.22 no.2
• /
• pp.135-143
• /
• 1986

This study was designed to investigate the role of calcium in the function of an isolated perfused rabbit kidney and its effect on the diuretic action of furosemide. The administrations of hydralazine and verapamil produced remarkable diuretic actions mainly by decreasing renal resistance. The administration of furosemide in combination with hydralazine or verapamil produced remarkable diuretic action and there was no difference between the two groups. The administration of quinidine produced a diuretic action in spite of vasoconstriction and potentiated the diuretic action of furosemide. In the calcium-free perfusion medium, the administration of calcium produced a marked diuretic action in spite of vasoconstriction and potentiated significantly the diuretic action of furosemide. The administration of quinidine did not alter renal function and the diuretic action of furosemide, but the combined administration of quinidine and calcium showed antidiuretic effect due to excessive vasoconstriction in the calcium-free perfusion medium. Although the administration of verapamil produced a slight diuretic action in the calcium-free perfusion medium, verapamil did not alter the diuretic action of calcium as well as the diuretic actions of furosemide alone and in combination with calcium. The results of this experiment show that calcium, verapamil and quinidine produced diuretic actions and calcium potentiates the diuretic action of furosemide.

• Biomolecules & Therapeutics
• /
• v.3 no.2
• /
• pp.104-110
• /
• 1995

Arachidonic acid (AA, C20 : 4, $\omega$-6) and eicosapentanoic acid (EPA,C20 : 5, $\omega$-3), which are polyunsaturated fatty acids forming eicosanoids, were tested for their effects on blood pressure in Wistar rats and SHR. AA is the most important precursor for the biosynthesis of eicosanoids which include the prostaglandins, prostacyclin (PGI$_2$), thromboxane $A_2$ (TXA$_2$) and the leukotriens. TXA$_2$is a potent vasoconstrictor and a powerful inducer of platelet aggregation causing myocardial infarction and hypertention. In contrast, PGI$_2$ induces vasodilation and inhibits platelet aggregation. In this study, AA markedly increased blood pressure, but its effect was antagonized by both EPA, a structural analog of AA, and dazmegrel, a TX synthetase inhibitor. Also, AA enhanced the antihypertensive effects of hydralazine and captopril, and EPA reduced TXA$_2$ production. These results indicate that the hypotensive effects of EPA might be closely related to the decrease in TXA$_2$ biosynthesis due to competitive inhibition by structural similarity of the EPA to the AA, the precursor of TXA$_2$.

• Journal of Chest Surgery
• /
• v.18 no.4
• /
• pp.732-739
• /
• 1985

This study was experimentally undertaken to evaluate the effect of the coronary vasodilator-mixed cardioplegic solution on myocardial protection during prolonged aortic cross-clamping. The dogs were divided into two groups: control group A[received hypothermic cardioplegic solution without any additive coronary vasodilator], and comparing group 8[received hypothermic cardioplegic solution, mixed with various coronary vasodilators and Inderal]. Group A further was divided into two subgroups: subgroup A-1[ischemic time, 90 minutes], and subgroup A-2 [ischemic time, 240 minutes]. Group B further was divided into five subgroups: subgroup B-1 [received papaverine mixed hypothermic cardioplegic solution], subgroup B-2[received nitroglycerin mixed hypothermic cardioplegic solution], subgroup B-3 [received nitroprusside mixed hypothermic cardioplegic solution, subgroup B-4[received hydralazine mixed hypothermic cardioplegic solution], and subgroup B-5 [received inderal mixed hypothermic cardioplegic solution]. The specimens from all of the subgroups were studied by electron microscopic examination. The specimens of subgroups [B-l, B-2 8-3, and B-4], received coronary vasodilators mixed hypothermic cardioplegic solutions, were also compared by methylene blue induced staining of the myocardium and coronary vessels. The results obtained were as followings: l. On electron microscopic examination, all of the specimens, including subgroup A-2, showed no irreversible change of the myocardium. But the best result was obtained from the subgroup B-l, treated by papaverine mixed hypothermic cardioplegic solution. The subgroup B-2, treated by nitroglycerin, was next. And the subgroup B-5, treated by Inderal, was agreeable, comparing the electron microscopic finding with control group in the effect of myocardial protection. 2. The distribution in the myocardium of cardioplegic solution was demonstrated with the aid of methylene blue staining in the subgroups of B-l, B-2, B-3, and B-4, and they were the groups treated by papaverine, nitroglycerin, nitroprusside, and hydralazine in their grouping order. The best result was obtained from the subgroup B-1 [papaverine]. The subgroup B-2 [nitroglycerin] was next. The subgroup B-3 [nitroprusside] was moderate in finding of the colorization. The subgroup B-4 [hydralazine] was the poorest in the distribution of the cardioplegic solution in the myocardium. From these results, it appeared that myocardial protection during ischemic arrest for open heart surgery could be enhanced considerably when coronary dilatation was assured.

• Journal of Chest Surgery
• /
• v.15 no.3
• /
• pp.338-345
• /
• 1982

An 11 year old boy with a preductal coarctation and a patent ductus arteriosus underwent ligation of the ductus and patch aortoplasty for correction of the coarctation. His postoperative course was complicated by a paradoxical hypertension and a transient mesenteric arteritis syndrome which were successfully managed with sodium nitroprusside, propranolol and hydralazine. His urine catecholamine tests were markedly elevated one week after the operation which returned to normal 4 days later. Some of the salient points ~n the pathogenesis and management of these problems are discussed.

• Korean Journal of Pharmacognosy
• /
• v.10 no.3
• /
• pp.125-135
• /
• 1979

This study was undertaken to search for a new antihypertensive or hypotensive agents in natural crude products in Korea. Betula schmidtii Regel, a tree belonging to the Betulaceae family, is cultivated for the most part of our country, and their cortecies or tree milk has been used as folk remedy, which exerted good antiinflammatory effect on rheumatic fever, arthritis or rheumatism. The rats were treated with several extracts from Betula schmidtii Regel, that is, extracts of water, methanol from inner cortecies, extracts of ether, methanol, hexane, chloroform or butanol from outer and total cortecies. In this experiment, we measured the blood pressure and heart rate in anesthetized rats, and atropine, diphenhydramine, phentolamine, propranolol, epinephrine, hexamethonium and hydralazine were pretreated prior to Betula extracts to clarify the mechanism of the hypotensive action. The results of the experiment were as follows; 1. BOIE(Betula outer cortex water-insoluble extract) and BICE(Betula inner cortex chloroform extract) elevated the blood pressure and heart rate. 2. BIME(Betula inner cortex methanol extract), BIBE(Betula inner cortex butanol extract) and BIWE (Betula inner cortex water extract) significantly lowered the blood pressure and heart rate. 3. With the pretreatment of hydralazine, the hypotensive effect of Betula schmidtii Regel was significantly blocked. From the above results, it is suggested that the hypotensive effect of Betula schmidtii Regel is due to the direct vasodilation of blood vessel.

• The Journal of Korean Medicine
• /
• v.18 no.1
• /
• pp.267-277
• /
• 1997

Experiments were performed to determine the effects of the Oyacksunkisan(烏藥順氣散) and Kamioyacksunkisan(加味烏藥順氣散) liquid extract on the hypertension and the pulse rate in Sprague-Dawley rat(SDR) and Spontaneous Hypertensive rats(SHR). The results were obtained as follows ; 1. Blood pressure was significantly decreased firstday and 11th day after administration of Oyacksunkisan extract and pretreatment of phentolamine. 2. Blood pressure and pulse rate were regulated first day after administration of Kamioyacksunkisan and blood pressure was significantly decreased after pretreatment of clonidine and phentolamine. 3. Oyacksunkisan and Kamioyacksunkisan didn't show any significant changes of blood pressure and pulse rate after pretreatment of prdpranolol, hydralazine and verapamil From the above result, it was concluded that Oyacksunkisan(烏藥順氣散) and Kamioyacksunkisan(加味烏藥順氣散) could be applied effectively to the hypertension.

• Biomolecules & Therapeutics
• /
• v.8 no.1
• /
• pp.93-98
• /
• 2000

This study has been carried out to investigate general pharmacological action of bamboo salt (jukyom) in terms of effects on central nervous system and cardiovascular system in experimental animals. After bamboo salt, crude salt or reagent-grade NaCl were orally administered into male ICR mice with dose of 2.0 g/kg, general behavioural syndromes such as body weight and locomotor activity, spontaneous motor activity, pento-barbital-induced sleeping time, muscle incoordination, electroshock-induced convulsion, body temperature and writhing response caused by 0.6% acetic acid solution were observed. Bamboo salt had no influences in these indices for examinition of effect on central nervous system. Additionally, conscious male Sprague Dawley rats fastened overnight won ere treated with bamboo salt, crude salt or reagent-grade NaCl (2.0 g/kg, p.o.) to examine the effect of these salts cardiovascular system. Systolic, median and diastolic food pressure and heart rate were dertemined using tail cuff indirect method. Treatment with Hydralazine (50 mg/kg, p.o) as a positive control produced the decreases in systolic, median and diastolic blood treasure and an increase in heart rate. whereas no changes were observed in bamboo salt, crude salt and reagent-grade NaCl treated groups. These results strongly suggest that bamboo salt may have no effects on general pharmacology of central nervous systems and cardio-vascular systems.

• YAKHAK HOEJI
• /
• v.33 no.4
• /
• pp.211-218
• /
• 1989

Twenty-six injectable drug products, many of which are administered by i.v. infusion, were studied for loss from aqueous solutions stored in polyvinyl chloride (PVC) infusion bags for various periods of time. The PVC infusion bags were stored in the dark room at room temperature for up to one month. Drugs stored in glass bottle served as controls. The solutions were assayed Spectrophotometrically at regular intervals. The effect of drug concentration and pH on the loss of drug from solution were studied. Octanol-water partition coefficients were used as a guage of lipid solubility of drugs. The elution of di(2-ethylhexyl)phthalate(DEHT) from PVC infusion bags was studied. For most of the drug studied, minimal loss from the aqueous solutions were observed over periods of storage time. Six of the drug products - Thiopental sodium, Hydralazine HCl, Thioridazine HCl, Trifluoperazine 2HCl, Metronidazole, Chlorpromazine HCl - were found to be lost a substantial extent. DEHP was found to be migrating from PVC infusion bags.

• Korean Circulation Journal
• /
• v.52 no.3
• /
• pp.173-197
• /
• 2022

Treatment options for patients with heart failure (HF) with reduced ejection fraction (HFrEF) have expanded considerably over the past few decades. Whereas neurohormonal modulation remains central to the management of patients with HFrEF, other pathways have been targeted with drugs that have novel mechanisms of action. The angiotensin receptor-neprilysin inhibitors (ARNIs) which enhance levels of compensatory molecules such as the natriuretic peptides while simultaneously providing angiotensin receptor blockade have emerged as the preferred strategy for inhibiting the renin angiotensin system. Sodium glucose cotransporter 2 (SGLT2) inhibitors which were developed as hypoglycemic agents have been shown to improve outcomes in patients with HF regardless of their diabetic status. These agents along with beta blockers and mineralocorticoid receptor antagonists are the core medical therapies for patients with HFrEF. Additional approaches using ivabradine to slow heart rate in patients with sinus rhythm, the hydralazine/isosorbide dinitrate combination to unload the heart, digoxin to provide inotropic support and vericiguat to augment cyclic guanosine monophosphate production have been shown in well-designed trials to have beneficial effects in the HFrEF population and are used as adjuncts to the core therapies in selected patients. This review provides an overview of the medical management of patients with HFrEF with focus on the major developments that have taken place in the field. It offers prospective of how these drugs should be employed in clinical practice and also a glimpse into some strategies that may prove to be useful in the future.